Prognosis

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Prognosis is an early-stage landscape with 0 programs across 1 company. The most active players are Bayer.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed6 · 40%

Unknown status6 · 40%

Recruiting2 · 13%

Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action

Recruiting·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 4·NCT05663242·300 enrolled

The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action

Recruiting·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 4·NCT05926336·1,316 enrolled

RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection

Active, not recruiting·WWest China Hospital·Phase 4·NCT04032860·104 enrolled

Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies

Completed· Bayer logo

Bayer·N/A·NCT02610153·1,013 enrolled

First Line TIP in Poor Prognosis TGCTs.

Completed·National Cancer Institute, Slovakia·Phase 2·NCT02414685·19 enrolled

A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis

Completed·BBarts & The London NHS Trust·Phase 2·NCT01782339·45 enrolled

Double Pick up in Poor Prognosis Women

Completed·CCRG UZ Brussel·Phase 4·NCT03846544·48 enrolled

Epidemiology, Management, Prognosis and Medical Cost Analysis of IHCA and OHCA

Completed·NNational Taiwan University Hospital·N/A·NCT03684616·100,000 enrolled

Prognosis in UC After First Biological

Completed·TTampere University Hospital·N/A·NCT05530122·192 enrolled

Comparison of PD1+T Cell Expression in Peripheral Blood for Cardiac Function Prognosis in Patients With Acute MI

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05251987·100 enrolled

DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease

Unknown status·UUniversity Hospital, Tours·N/A·NCT06230562·60 enrolled

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099188·27 enrolled

Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function

Unknown status·QQilu Hospital of Shandong University·N/A·NCT06039072·120 enrolled

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099175·41 enrolled

Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis

Unknown status·SSun Yat-sen University·N/A·NCT02505113·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)